Last reviewed · How we verify

NCT06886711

Research on the Role of Probiotics in Human Intestinal Health

Not yet recruiting NA Last updated 20 March 2025
What this trial tests

NA trial testing Probiotic in Intestinal Microbiota in 45 participants. Not yet recruiting.

Timeline
10 March 2025
Primary endpoint
30 September 2025
30 December 2025

Quick facts

Lead sponsorWecare Probiotics Co., Ltd.
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment45
Start date10 March 2025
Primary completion30 September 2025
Estimated completion30 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Wecare Probiotics Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, any sex, with Intestinal Microbiota. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the efectiveness and safety of Bifidobacterium bifidum BBi32 as a food supplement compared to a placebo in improving intestinal andimmune functions in healthy adults.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical Safety and Tolerability of <i>Bifidobacterium bifidum</i> BBi32: An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial With Genomic and In Vitro Corroboration.
    Fang S, Wang S, Liu Y, Zhu C, et al · · 2026 · PMID 41523287 · DOI 10.1002/fsn3.71420

Verify or expand the search:

Other trials of Probiotic

Trials testing the same drug.

Other recruiting trials for Intestinal Microbiota

Currently open trials in the same condition.

Other Wecare Probiotics Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06886711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing